SNCA: Alpha-synuclein
Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on SNCA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Prasinezumab | Phase 2 | Roche | Antibody | Binding agentAlpha-synuclein binding agent | 4 |
| Cinpanemab | Phase 2 | Biogen | Antibody | InhibitorAlpha-synuclein inhibitor | 0 |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Prasinezumab | Phase 3 | Recruiting | Hoffmann-La Roche | Sep 15, 2025 |
| Prevent Cognitive Decline in GBA-associated Parkinson's Disease | Prasinezumab | Phase 2 | Recruiting | University Hospital Tuebingen | Jul 8, 2025 |
| A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | Prasinezumab | Phase 2 | Active, not recruiting | Hoffmann-La Roche | Mar 2, 2021 |
| A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | Prasinezumab | Phase 2 | Active, not recruiting | Hoffmann-La Roche | Apr 4, 2017 |
- Late-onset Parkinson disease0.79
- Young-onset Parkinson disease0.77
- Parkinson disease0.76
- Lewy body dementia0.74
- AL amyloidosis0.46
- REM sleep behavior disorder0.38
- Parkinsonian-pyramidal syndrome0.37
- Insomnia0.34
- Cachexia0.32
- Schizophrenia0.31
- COVID-190.28
- Benign chondrogenic neoplasm0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6152, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P37840, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets